Royal Bank of Canada
XLO icon

Royal Bank of Canada’s Xilio Therapeutics XLO Stock Holding History

Royal Bank of Canada’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-91
Closed -$1K – 7865
2026
Q1 		$1K Buy
+91
New +$745 ﹤0.01% 6976
2024
Q3 		– Sell
-26
Closed – – 7535
2024
Q2 		$0 Sell
26
-12
-32% -$188 ﹤0.01% 7604
2024
Q1 		$1K Buy
38
+5
+15% +$48 ﹤0.01% 6883
2023
Q4 		$0 Buy
33
+8
+32% +$158 ﹤0.01% 7650
2023
Q3 		$1K Sell
25
-88
-78% -$3.28K ﹤0.01% 6961
2023
Q2 		$4K Buy
113
+61
+117% +$2.6K ﹤0.01% 6754
2023
Q1 		$2K Buy
+52
New +$2.28K ﹤0.01% 6810
2022
Q2 		– Sell
-34
Closed -$3K – 7765
2022
Q1 		$3K Sell
34
-79
-70% -$12.5K ﹤0.01% 7411
2021
Q4 		$25K Buy
+113
New +$26.9K ﹤0.01% 6699

Other funds holding XLO

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $526M AUM 175.27% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Royal Bank of Canada's XLO Position: Q2 2026 in Review

Royal Bank of Canada sold out of Xilio Therapeutics (XLO) in Q2 2026, closing a stake of 91 shares — an estimated $1K sold.

Royal Bank of Canada first reported a position in XLO in Q4 2021 and held it in 9 quarters. The position peaked at $25K in Q4 2021. 24 funds tracked by Wall St. Rank hold XLO as of Q2 2026.

  • Royal Bank of Canada reported no remaining Xilio Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Royal Bank of Canada sold 91 Xilio Therapeutics shares in Q2 2026, an estimated $1K.
  • Royal Bank of Canada first reported a position in Xilio Therapeutics in Q4 2021 and held it in 9 quarters.
  • Royal Bank of Canada's Xilio Therapeutics position peaked at $25K in Q4 2021.
  • 24 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.